• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境和PD-L1颗粒度的特征揭示了癌症相关肌成纤维细胞在非浸润性膀胱癌中的预后价值。

Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.

作者信息

Cañizo Carmen G, Guerrero-Ramos Félix, Perez Escavy Mercedes, Lodewijk Iris, Suárez-Cabrera Cristian, Morales Lucía, Nunes Sandra P, Munera-Maravilla Ester, Rubio Carolina, Sánchez Rebeca, Rodriguez-Izquierdo Marta, Martínez de Villarreal Jaime, Real Francisco X, Castellano Daniel, Martín-Arriscado Cristina, Lora Pablos David, Rodríguez Antolín Alfredo, Dueñas Marta, Paramio Jesús M, Martínez Victor G

机构信息

Urology Department, University Hospital '12 de Octubre', Madrid, Spain.

Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain.

出版信息

Oncoimmunology. 2025 Dec;14(1):2438291. doi: 10.1080/2162402X.2024.2438291. Epub 2024 Dec 19.

DOI:10.1080/2162402X.2024.2438291
PMID:39698899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11660370/
Abstract

High-risk non-muscle-invasive bladder cancer (NMIBC) presents high recurrence and progression rates. Despite the use of Bacillus Calmette-Guérin gold-standard immunotherapy and the recent irruption of anti-PD-1/PD-L1 drugs, we are missing a comprehensive understanding of the tumor microenvironment (TME) that may help us find biomarkers associated to treatment outcome. Here, we prospectively analyzed TME composition and PD-L1 expression of tumor and non-tumoral tissue biopsies from 73 NMIBC patients and used scRNA-seq, transcriptomic cohorts and tissue micro-array to validate the prognostic value of cell types of interest. Compared to non-tumoral tissue, NMIBC presented microvascular alterations, increased cancer-associated fibroblast (CAF) and myofibroblast (myoCAF) presence, and varied immune cell distribution, such as increased macrophage infiltration. Heterogeneous PD-L1 expression was observed across subsets, with macrophages showing the highest expression levels, but cancer cells as the primary potential anti-PD-L1 binding targets. Unbiased analysis revealed that myoCAF and M2-like macrophages are specifically enriched in high-grade NMIBC tumors. The topological distribution of these two cell types changed as NMIBC progresses, as shown by immunofluorescence. Only myoCAFs were associated with higher rates of progression and recurrence in three independent cohorts (888 total patients), reaching prediction values comparable to transcriptomic classes, which we further validated using tissue micro-array. Our study provides a roadmap to establish the landscape of the NMIBC TME, highlighting myoCAFs as potential prognostic markers.

摘要

高危非肌肉浸润性膀胱癌(NMIBC)具有较高的复发率和进展率。尽管使用了卡介苗(Bacillus Calmette-Guérin)这一黄金标准免疫疗法,且近期抗PD-1/PD-L1药物也已出现,但我们仍缺乏对肿瘤微环境(TME)的全面了解,而这可能有助于我们找到与治疗结果相关的生物标志物。在此,我们前瞻性分析了73例NMIBC患者肿瘤和非肿瘤组织活检的TME组成及PD-L1表达,并使用单细胞RNA测序(scRNA-seq)、转录组队列和组织微阵列来验证感兴趣细胞类型的预后价值。与非肿瘤组织相比,NMIBC表现出微血管改变、癌症相关成纤维细胞(CAF)和肌成纤维细胞(myoCAF)增多,以及免疫细胞分布各异,如巨噬细胞浸润增加。在各亚组中观察到异质性PD-L1表达,巨噬细胞表达水平最高,但癌细胞是主要的潜在抗PD-L1结合靶点。无偏分析显示,myoCAF和M2样巨噬细胞在高级别NMIBC肿瘤中特异性富集。免疫荧光显示,随着NMIBC进展,这两种细胞类型的拓扑分布发生变化。在三个独立队列(共888例患者)中,只有myoCAF与更高的进展率和复发率相关,其预测价值与转录组分类相当,我们使用组织微阵列进一步验证了这一点。我们的研究为建立NMIBC TME格局提供了路线图,突出了myoCAF作为潜在预后标志物的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/aeb4410e515f/KONI_A_2438291_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/206be508bbde/KONI_A_2438291_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/3213a2583605/KONI_A_2438291_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/07f8372f65d3/KONI_A_2438291_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/79ce61c75570/KONI_A_2438291_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/df24881c1c4b/KONI_A_2438291_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/486d4e39f2b7/KONI_A_2438291_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/aeb4410e515f/KONI_A_2438291_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/206be508bbde/KONI_A_2438291_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/3213a2583605/KONI_A_2438291_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/07f8372f65d3/KONI_A_2438291_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/79ce61c75570/KONI_A_2438291_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/df24881c1c4b/KONI_A_2438291_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/486d4e39f2b7/KONI_A_2438291_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d8/11660370/aeb4410e515f/KONI_A_2438291_F0007_OC.jpg

相似文献

1
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.肿瘤微环境和PD-L1颗粒度的特征揭示了癌症相关肌成纤维细胞在非浸润性膀胱癌中的预后价值。
Oncoimmunology. 2025 Dec;14(1):2438291. doi: 10.1080/2162402X.2024.2438291. Epub 2024 Dec 19.
2
Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.基于微环境免疫类型和程序性死亡受体配体1(PD-L1)的基因组分层,用于定制膀胱癌的治疗策略。
BMC Cancer. 2021 May 31;21(1):646. doi: 10.1186/s12885-021-08350-1.
3
Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.BCG 免疫治疗治疗初发高级别非肌肉浸润性膀胱癌患者治疗前后 PD-L1 表达的预后意义。
World J Urol. 2020 Oct;38(10):2537-2545. doi: 10.1007/s00345-019-03065-2. Epub 2020 Jan 3.
4
PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.PD-L1 表达和免疫细胞模式与接受 BCG 治疗的 HR-NMIBC 患者的无病生存相关。
World J Urol. 2021 Nov;39(11):4055-4065. doi: 10.1007/s00345-020-03329-2. Epub 2020 Jul 14.
5
Loss of Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Tumor Microenvironment and Response to BCG Immunotherapy in a Murine Orthotopic Model of Bladder Cancer.谷胱甘肽-S-转移酶θ2(GSTT2)缺失对膀胱癌小鼠原位模型肿瘤微环境及卡介苗免疫治疗反应的影响
Int J Mol Sci. 2024 Dec 11;25(24):13296. doi: 10.3390/ijms252413296.
6
The impact of POSTN on tumor cell behavior and the tumor microenvironment in lung adenocarcinoma.POSTN对肺腺癌肿瘤细胞行为及肿瘤微环境的影响。
Int Immunopharmacol. 2025 Jan 3;145:113713. doi: 10.1016/j.intimp.2024.113713. Epub 2024 Dec 13.
7
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.高危非肌层浸润性膀胱癌中程序性死亡受体配体1(PD-L1)的表达并非卡介苗(BCG)治疗反应的生物标志物。
World J Urol. 2025 Jan 3;43(1):57. doi: 10.1007/s00345-024-05392-5.
8
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.高级别 T1 期与肌层浸润性膀胱癌中 PD-L1 的差异表达及其预后意义。
J Urol. 2017 Oct;198(4):817-823. doi: 10.1016/j.juro.2017.04.102. Epub 2017 May 6.
9
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.膀胱尿路上皮癌中免疫检查点相关分子的信使核糖核酸表达与蛋白质表达的相关性:一项回顾性研究。
Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.
10
Single-cell RNA sequencing analysis reveals the dynamic changes in the tumor microenvironment during NMIBC recurrence.单细胞RNA测序分析揭示了非肌层浸润性膀胱癌复发期间肿瘤微环境的动态变化。
Apoptosis. 2025 Feb;30(1-2):282-296. doi: 10.1007/s10495-024-02044-2. Epub 2024 Dec 4.

引用本文的文献

1
Expression of PD-1 and PD-L1 in BCG-treated NMIBC.卡介苗治疗的非肌层浸润性膀胱癌中PD-1和PD-L1的表达
Bladder Cancer. 2025 Aug 17;11(3):23523735251368683. doi: 10.1177/23523735251368683. eCollection 2025 Jul-Sep.

本文引用的文献

1
NAD metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.NAD 代谢酶 NNMT 在癌症相关成纤维细胞中通过调节膀胱癌中的巨噬细胞促进肿瘤进展和对免疫治疗的抵抗。
J Immunother Cancer. 2024 Jul 27;12(7):e009281. doi: 10.1136/jitc-2024-009281.
2
FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.膀胱癌中 FGFR3 的改变刺激丝氨酸合成,诱导免疫惰性巨噬细胞抑制 T 细胞募集和激活。
Cancer Res. 2023 Dec 15;83(24):4030-4046. doi: 10.1158/0008-5472.CAN-23-1065.
3
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
atezolizumab 在卡介苗无应答高危非肌肉浸润性膀胱癌中的 2 期临床试验:SWOG S1605。
Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.
4
Basonuclin-2 regulates extracellular matrix production and degradation.Basonuclin-2 调节细胞外基质的产生和降解。
Life Sci Alliance. 2023 Aug 3;6(10). doi: 10.26508/lsa.202301984. Print 2023 Oct.
5
Stromal circuits involving tumor-associated macrophages and cancer-associated fibroblasts.涉及肿瘤相关巨噬细胞和癌症相关成纤维细胞的基质回路。
Front Immunol. 2023 Jun 5;14:1194642. doi: 10.3389/fimmu.2023.1194642. eCollection 2023.
6
Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin.非肌肉浸润性膀胱癌分子亚型预测对卡介苗膀胱内灌注治疗的差异性反应。
Sci Transl Med. 2023 May 24;15(697):eabn4118. doi: 10.1126/scitranslmed.abn4118.
7
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.肿瘤微环境作为预测非肌肉浸润性膀胱癌免疫治疗的因素。
Cancer Immunol Immunother. 2023 Jul;72(7):1971-1989. doi: 10.1007/s00262-023-03376-9. Epub 2023 Mar 16.
8
Micro-mechanical fingerprints of the rat bladder change in actinic cystitis and tumor presence.大鼠膀胱在光化性膀胱炎和肿瘤存在时的微机械指纹发生变化。
Commun Biol. 2023 Feb 24;6(1):217. doi: 10.1038/s42003-023-04572-0.
9
Interferon-dependent SLC14A1 cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer.干扰素依赖的 SLC14A1 癌症相关成纤维细胞通过 WNT5A 在膀胱癌中促进癌症干性。
Cancer Cell. 2022 Dec 12;40(12):1550-1565.e7. doi: 10.1016/j.ccell.2022.11.005. Epub 2022 Dec 1.
10
Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer.高 T 细胞耗竭和尿肿瘤 DNA 水平与非肌肉浸润性膀胱癌患者卡介苗失败相关。
Eur Urol. 2022 Dec;82(6):646-656. doi: 10.1016/j.eururo.2022.09.008. Epub 2022 Oct 7.